BIOMAT Database Logo BIOMAT Database Logo

Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines. 1988

R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
Department of Pharmacology, Smith Kline & French Laboratories, Philadelphia, Pennsylvania.

A series of alpha adrenoceptor antagonists, including both reference compounds and the novel benzazepine antagonists, SK&F 86466 (6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine) and two of its 9-substituted derivatives, SK&F 101253 and SK&F 104078, were tested in vitro for affinity at central and peripheral alpha adrenoceptor subtypes. Peripheral alpha-1 adrenoceptor antagonist potency of these agents, as assessed by the receptor dissociation constant (KB) against norepinephrine-induced contraction in the rabbit aorta, correlated with the Ki value for inhibition of [3H]prazosin binding to central alpha-1 adrenoceptors in rat brain homogenates. Central alpha-2 adrenoceptor affinity, measured as the Ki for inhibition of [3H]rauwolscine binding to rat brain homogenates, correlated well with antagonist activity at peripheral postjunctional alpha-2 adrenoceptors as reflected by the KB against B-HT 920-induced contraction in canine saphenous vein. The 9-substituted benzazepines, SK&F 101253 and SK&F 104078, produce preferential blockade of postjunctional vs. prejunctional alpha-2 adrenoceptors in peripheral models. The high affinity of SK&F 104078 for postjunctional alpha-2 adrenoceptors in the canine saphenous vein was confirmed by its ability to inhibit [3H]rauwolscine binding to postjunctional alpha-2 adrenoceptors in this tissue. The observation that the Ki values for these antagonists against [3H] rauwolscine binding correlate with their KB values at the postjunctional alpha-2 adrenoceptors, rather than those at the prejunctional neuroinhibitory alpha-2 adrenoceptor, suggests a pharmacologic similarity between the postjunctional vascular alpha-2 adrenoceptors and the central [3H]rauwolscine binding site.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D011224 Prazosin A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION. Furazosin,Minipress,Pratsiol,Prazosin HCL,Prazosin Hydrochloride,HCL, Prazosin,Hydrochloride, Prazosin
D011817 Rabbits A burrowing plant-eating mammal with hind limbs that are longer than its fore limbs. It belongs to the family Leporidae of the order Lagomorpha, and in contrast to hares, possesses 22 instead of 24 pairs of chromosomes. Belgian Hare,New Zealand Rabbit,New Zealand Rabbits,New Zealand White Rabbit,Rabbit,Rabbit, Domestic,Chinchilla Rabbits,NZW Rabbits,New Zealand White Rabbits,Oryctolagus cuniculus,Chinchilla Rabbit,Domestic Rabbit,Domestic Rabbits,Hare, Belgian,NZW Rabbit,Rabbit, Chinchilla,Rabbit, NZW,Rabbit, New Zealand,Rabbits, Chinchilla,Rabbits, Domestic,Rabbits, NZW,Rabbits, New Zealand,Zealand Rabbit, New,Zealand Rabbits, New,cuniculus, Oryctolagus
D011942 Receptors, Adrenergic, alpha One of the two major pharmacological subdivisions of adrenergic receptors that were originally defined by the relative potencies of various adrenergic compounds. The alpha receptors were initially described as excitatory receptors that post-junctionally stimulate SMOOTH MUSCLE contraction. However, further analysis has revealed a more complex picture involving several alpha receptor subtypes and their involvement in feedback regulation. Adrenergic alpha-Receptor,Adrenergic alpha-Receptors,Receptors, alpha-Adrenergic,alpha-Adrenergic Receptor,alpha-Adrenergic Receptors,Receptor, Adrenergic, alpha,Adrenergic alpha Receptor,Adrenergic alpha Receptors,Receptor, alpha-Adrenergic,Receptors, alpha Adrenergic,alpha Adrenergic Receptor,alpha Adrenergic Receptors,alpha-Receptor, Adrenergic,alpha-Receptors, Adrenergic
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000317 Adrenergic alpha-Antagonists Drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma. Adrenergic alpha-Receptor Blockaders,alpha-Adrenergic Blocking Agents,alpha-Adrenergic Receptor Blockaders,alpha-Blockers, Adrenergic,Adrenergic alpha-Blockers,alpha-Adrenergic Antagonists,alpha-Adrenergic Blockers,Adrenergic alpha Antagonists,Adrenergic alpha Blockers,Adrenergic alpha Receptor Blockaders,Agents, alpha-Adrenergic Blocking,Antagonists, alpha-Adrenergic,Blockaders, Adrenergic alpha-Receptor,Blockaders, alpha-Adrenergic Receptor,Blockers, alpha-Adrenergic,Blocking Agents, alpha-Adrenergic,Receptor Blockaders, alpha-Adrenergic,alpha Adrenergic Antagonists,alpha Adrenergic Blockers,alpha Adrenergic Blocking Agents,alpha Adrenergic Receptor Blockaders,alpha Blockers, Adrenergic,alpha-Antagonists, Adrenergic,alpha-Receptor Blockaders, Adrenergic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001552 Benzazepines Compounds with BENZENE fused to AZEPINES.
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species

Related Publications

R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
No evidence for differences between pre- and postjunctional alpha 2-adrenoceptors in the periphery.
January 1990, British journal of pharmacology,
R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
Evidence that SK & F 104078 does not differentiate between pre- and postjunctional alpha 2-adrenoceptors.
October 1988, Naunyn-Schmiedeberg's archives of pharmacology,
R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
Pharmacologic differentiation between pre- and postjunctional alpha 2-adrenoceptors by SK&F 104078.
October 1987, Naunyn-Schmiedeberg's archives of pharmacology,
R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
Evidence for heterogeneity of prejunctional alpha-2-adrenoceptors.
January 1991, Pharmacology,
R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
Heterogeneity of postjunctional vascular alpha-adrenoceptors and handling of calcium.
January 1982, Journal of cardiovascular pharmacology,
R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
No evidence for differences between pre- and post-junctional alpha 2-adrenoceptors.
October 1985, British journal of pharmacology,
R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
Evidence for postjunctional vascular alpha 2-adrenoceptors in peripheral vascular regulation in man.
September 1983, Clinical science (London, England : 1979),
R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
Functional evidence for heterogeneity of ocular alpha 2-adrenoceptors.
January 1990, Proceedings of the Western Pharmacology Society,
R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
Pharmacological evidence for heterogeneity of ocular alpha 2 adrenoceptors.
October 1992, Current eye research,
R N Daly, and A C Sulpizio, and B Levitt, and R M DeMarinis, and J W Regan, and R R Ruffolo, and J P Hieble
Evidence for existence of postjunctional alpha 1- and alpha 2-adrenoceptors in cat pulmonary vascular bed.
October 1985, The American journal of physiology,
Copied contents to your clipboard!